Gibson Peter G, McDonald Vanessa M
National Health and Medical Research Council Centre of Excellence in Severe Asthma, The University of Newcastle, Newcastle, New South Wales, Australia.
Priority Research Centre for Healthy Lungs, The University of Newcastle, Newcastle, New South Wales, Australia.
Intern Med J. 2017 Jun;47(6):623-631. doi: 10.1111/imj.13441.
Severe asthma is a complex heterogeneous disease that is refractory to standard treatment and is complicated by multiple comorbidities and risk factors. In mild to moderate asthma, the burden of disease can be minimised by inhaled corticosteroids, bronchodilators and self-management education. In severe asthma, however, management is more complex. When patients with asthma continue to experience symptoms and exacerbations despite optimal management, severe refractory asthma (SRA) should be suspected and confirmed, and other aetiologies ruled out. Once a diagnosis of SRA is established, patients should undergo a systematic and multidimensional assessment to identify inflammatory endotypes, risk factors and comorbidities, with targeted and individualised management initiated. We describe a practical approach to assessment and management of patients with SRA.
重度哮喘是一种复杂的异质性疾病,对标准治疗无效,且伴有多种合并症和风险因素。在轻度至中度哮喘中,吸入性糖皮质激素、支气管扩张剂和自我管理教育可将疾病负担降至最低。然而,重度哮喘的管理更为复杂。当哮喘患者尽管接受了最佳管理仍持续出现症状和病情加重时,应怀疑并确诊为重度难治性哮喘(SRA),并排除其他病因。一旦确诊为SRA,患者应接受系统的多维评估,以确定炎症亚型、风险因素和合并症,并启动针对性的个体化管理。我们描述了一种对SRA患者进行评估和管理的实用方法。